{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T11:42:28Z","timestamp":1744026148072},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1989,1,1]],"date-time":"1989-01-01T00:00:00Z","timestamp":599616000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1989]]},"DOI":"10.1007\/bf00694342","type":"journal-article","created":{"date-parts":[[2004,11,29]],"date-time":"2004-11-29T18:20:35Z","timestamp":1101752435000},"page":"70-72","source":"Crossref","is-referenced-by-count":28,"title":["Tubular nephrotoxicity during long-term ifosfamide and mesna therapy"],"prefix":"10.1007","volume":"25","author":[{"given":"Marshall P.","family":"Goren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles B.","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary J.","family":"Viar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","first-page":"48","volume":"6","author":"N Abeling","year":"1987","unstructured":"Abeling N, Kraker J de, Gennip A van (1987) Abnormal plasma and urinary amino acid patterns in children on ifosfamide treatment (abstract). Proc Annu Meet Am Soc Clin Oncol 6: 48","journal-title":"Proc Annu Meet Am Soc Clin Oncol"},{"key":"CR2","first-page":"499","volume":"69","author":"KH Antman","year":"1985","unstructured":"Antman KH, Montella D, Rosenbaum C, Schwen M (1985) Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rep 69: 499","journal-title":"Cancer Treat Rep"},{"issue":"Suppl A","key":"CR3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0305-7372(83)80005-X","volume":"10","author":"N Brock","year":"1983","unstructured":"Brock N, Pohl J (1983) The development of mesna for regional detoxification. Cancer Treat Rev 10 [Suppl A]: 33","journal-title":"Cancer Treat Rev"},{"key":"CR4","first-page":"375","volume":"58","author":"RA Defronzo","year":"1974","unstructured":"Defronzo RA, Abeloff M, Braine H, Humphrey RL, David PJ (1974) Renal dysfunction after treatment with isophosphamide (NSC-109724). Cancer Chemother Rep 58: 375","journal-title":"Cancer Chemother Rep"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF00265383","volume":"9","author":"G Falkson","year":"1982","unstructured":"Falkson G, Van Dyk JJ, Stapelberg R, Falkson HC (1982) Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment. Cancer Chemother Pharmacol 9: 81","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR6","first-page":"1103","volume":"64","author":"SD Fossa","year":"1980","unstructured":"Fossa SD, Talle K (1980) Treatment of metastatic renal cancer with ifosfamide and mesnum with and without irradiation. Cancer Treat Rep 64: 1103","journal-title":"Cancer Treat Rep"},{"key":"CR7","first-page":"127","volume":"71","author":"MP Goren","year":"1987","unstructured":"Goren MP, Wright RK, Horowitz ME, Pratt CB (1987) Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna. Cancer Treat Rep 71: 127","journal-title":"Cancer Treat Rep"},{"key":"CR8","first-page":"1457","volume":"47","author":"MP Goren","year":"1987","unstructured":"Goren MP, Wright RK, Pratt CB, Horowitz ME, Dodge RK, Viar MJ, Kovnar EH (1987) Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by priorcis-diamminedichloroplatinum(II) therapy. Cancer Res 47: 1457","journal-title":"Cancer Res"},{"key":"CR9","first-page":"17","volume":"1","author":"M Hacke","year":"1983","unstructured":"Hacke M, Schmoll HJ, Alt JM, Baumann K, Stolte H (1983) Nephrotoxicity ofcis-diamminedichloroplatinum with or without ifosfamide in cancer treatment. Clin Physiol Biochem 1: 17","journal-title":"Clin Physiol Biochem"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1200\/JCO.1985.3.3.367","volume":"3","author":"Sr PJ Loehrer","year":"1985","unstructured":"Loehrer PJ Sr, Williams SD, Einhorn LH, Ansari R (1985) Ifosfamide: an active drug in the treatment of adenocarcinoma of the pancreas. J Clin Oncol 3: 367","journal-title":"J Clin Oncol"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF00647256","volume":"23","author":"M Moncreif","year":"1989","unstructured":"Moncreif M, Foot A (1989) Fanconi syndrome after ifosfamide. Cancer Chemother Pharmacol 23: 121","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/1097-0142(19890215)63:4<649::AID-CNCR2820630408>3.0.CO;2-Z","volume":"63","author":"WP Patterson","year":"1989","unstructured":"Patterson WP, Khojasteh A (1989) Ifosfamide-induced renal tubular defects. Cancer 63: 649","journal-title":"Cancer"},{"key":"CR13","first-page":"131","volume":"71","author":"CB Pratt","year":"1987","unstructured":"Pratt CB, Horowitz ME, Meyer WH, Etcubanas E, Thompson EI, Douglass EC, Wilimas JA, Hayes FA, Green AA (1987) Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep 71: 131","journal-title":"Cancer Treat Rep"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0277-5379(84)90093-2","volume":"20","author":"G Sangster","year":"1981","unstructured":"Sangster G, Kaye SB, Calman KC, Dalton JF (1981) Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity. Eur J Cancer Clin Oncol 20: 435","journal-title":"Eur J Cancer Clin Oncol"},{"key":"CR15","first-page":"69","volume":"11","author":"RC Stuart-Harris","year":"1983","unstructured":"Stuart-Harris RC, Harper PG, Parsons CA, Kaye SB, Mooney CA, Gowing NF, Wiltshaw E (1983) High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. Cancer Chemother Pharmacol 11: 69","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR16","first-page":"921","volume":"32","author":"JJ Dyk Van","year":"1972","unstructured":"Van Dyk JJ, Falkson HC, Van der Merwe AM, Falkson G (1972) Unexpected toxicity in patients treated with iphosphamide. Cancer Res 32: 921","journal-title":"Cancer Res"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/jnci\/80.8.556","volume":"80","author":"M Zalupski","year":"1988","unstructured":"Zalupski M, Baker LH (1988) Ifosfamide. J Natl Cancer Inst 80: 556","journal-title":"J Natl Cancer Inst"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00694342.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00694342\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00694342","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T09:59:37Z","timestamp":1554458377000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00694342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1989]]}},"alternative-id":["BF00694342"],"URL":"https:\/\/doi.org\/10.1007\/bf00694342","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1989]]}}}